EMAP-II significantly inhibits the activity of pancreatic ductal adenocarcinoma cells (Schwarz et al., 2010) and exerts anti-cancer effects in prostate adenocarcinoma xenografts (Reznikov et al., 2007). This evidence concerns the gene AIMP1 and pancreatic ductal adenocarcinoma.